The role of host immune response and apoptosis in patients with laryngeal squamous cell carcinoma

ORL

Volumn 69, Issue 3, 2007, Pages 159-166

  Gomatos, I P ^a,c   Georgiou, A ^b   Giotakis, J ^b   Manolopoulos, L ^b   Apostolou, K ^a   Chatzigianni, E ^a   Albanopoulos, K ^a   Ferekidou, E ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b HIPPOKRATION HOSPITAL   (Greece)

^c NONE   (Greece)

Author keywords

bax; bcl 2; HLA DR; Laryngeal cancer

Indexed keywords

CISPLATIN; HLA DR ANTIGEN; PROTEIN BAX; PROTEIN BCL 2;

ADULT; AGED; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LARYNGECTOMY; LARYNX CARCINOMA; MALE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE; STROMA CELL; TREATMENT OUTCOME; TUMOR CELL;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-2-ASSOCIATED X PROTEIN; BIOLOGICAL MARKERS; CARCINOMA, SQUAMOUS CELL; FEMALE; FOLLOW-UP STUDIES; HLA-DR ANTIGENS; HUMANS; IMMUNOHISTOCHEMISTRY; LARYNGEAL NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RETROSPECTIVE STUDIES; STROMAL CELLS;

EID: 34247151694     PISSN: 03011569     EISSN: None     Source Type: Journal    
DOI: 10.1159/000099225     Document Type: Article

References (19)

1. Sikorska B, Danilewicz M, Wagrowska-Danilewicz M: HLA-DR expression is a significant prognostic factor in laryngeal cancer. A morphometric study. APMIS 1999;107:383-388.
2. Accola RS, Scupoli MT, Cambiaggi C, Tosi G, Sartoris S: Cell lineage-specific and developmental stage-specific controls of MHC class-II-antigen expression. Int J Cancer Suppl 1991;6:20-25.
3. Schendel DJ, Oberneder R, Falk CS, Jantzer P, Kressenstein S, Maget B, Hofstetter A, Riethmuller G, Nossner E: Cellular and molecular analyses of major histocompatibility complex (MHC) restricted and non-MHC-restricted effector cells recognizing renal cell carcinomas: problems and perspectives for immunotherapy. J Mol Med 1997;75:400-413.
4. Jäckel MC, Dorudian MA, Marx D, Brinck U, Schauer A, Steiner W: Spontaneous apoptosis in laryngeal squamous cell carcinoma is independent of bcl-2 and bax protein expression. Cancer 1999;15:591-599.
5. Pruneri G, Pignataro L, Carboni N, Ronchetti D, Cesana BM, Ottaviani A, Neri A, Buffa R: Clinical relevance of p53 and bcl-2 protein over-expression in laryngeal squamous-cell carcinoma. Int J Cancer 1998;79:263-268.
6. Bertho N, Drenou B, Laupeze B, Berre CL, Amiot L, Grosset JM, Fardel O, Charron D, Mooney N, Fauchet R: HLA-DR-mediated apoptosis susceptibility discriminates differentiation stages of dendritic/monocytic APC. J Immunol 2000;164:2379-2385.
7. Kunihiro M, Tanaka S, Haruma K, Yoshihara M, Sumii K, Kajiyama G, Shimamoto F: Combined expression of HLA-DR antigen and proliferating cell nuclear antigen correlate with colorectal cancer prognosis. Oncology 1998;55:326-333.
8. Esteban F, Ruiz-Cabello F, Concha A, Sanchez-Rozas JA, Garrido F: HLA-DR expression is associated with excellent prognosis in squamous cell carcinoma of the larynx. Clin Expl Metastasis 1990;8:319-328.
9. Zaloudik J, Moore M, Ghosh AK, Mechl Z, Rejthar A: DNA content and MHC class II antigen expression in malignant melanoma: clinical course. J Clin Pathol 1988;41:1078-1084.
10. Konstadoulakis MM, Bland KI: Molecular biology of breast cancer: integration of cellular and molecular concepts into therapeutic strategies. R I Med 1995;78:257-260.
11. Hsu MM, Lin BL: Characterization of T cell subset using monoclonal antibodies in nasopharyngeal carcinoma patients. Ann Otol Rhinol Laryngol 1986;95:298-301.
12. Hilton DA, West KP: An evaluation of the prognostic significance of HLA-DR expression in gastric carcinoma. Cancer 1990;66:1154-1157.
13. Bilim V, Tomita Y, Kawasaki T, Katagiri A, Imai T, Takeda M, Takahashi K: Prognostic value of bcl-2 and p53 expression in urinary tract transitional cell cancer. J Natl Cancer Inst 1996;88:686-688.
14. Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K, Kitada S, Reed JC: Immunohistochemical analysis of bcl-2, bax, bcl-x, and mcl-1 expression in prostate cancers. Am J Pathol 1996;148:1567-1576.
15. Sasatomi E, Tokunaga O, Miyazaki K: Spontaneous apoptosis in gallbladder carcinoma: relationships with clinicopathologic factors, expression of E-cadherin, bcl-2 protooncogene and bcl-2 oncosuppressor gene. Cancer 1996;78:2101-2110.
16. Jordan RCK, Catzavelos GC, Barrett AW, Speight PM: Differential expression of bcl-2 and bax in squamous cell carcinomas of the oral cavity. Eur J Cancer B Oral Oncol 1996;32:394-400.
17. Koshida Y, Saegusa M, Okayasu I: Apoptosis, cell proliferation and expression of bcl-2 and bax in gastric carcinomas: immunohistochemical and clinicopathological study. Br J Cancer 1997;75:367-373.
18. Binder C, Marx D, Overhoff R, Binder L, Schauer A, Hiddemann W: Bcl-2 protein expression in breast cancer in relation to established prognostic factors and other clinicopathological variables. Ann Oncol 1995;6:1005-1010.
19. Öfner D, Riehemann K, Maier H, Riedmann B, Nehoda H, Totsch M, Bocker W, Jasani B, Schmid KW: Immunohistochemically detectable bcl-2 expression in colorectal carcinoma: correlation with tumor stage and patient survival. Br J Cancer 1995;72:981-985.